Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma TrialLucas Moreno, Karsten Nysom, Nicolas U. Gerber et al.|Journal of Clinical Oncology|2024Cited by 25
Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumoursDahat A. Hussein, Guy Makin, Karen E. Brookes et al.|British Journal of Cancer|2009Cited by 15
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II TrialJuliet C. Gray, Lucas Moreno, Rebekah Weston et al.|Journal of Clinical Oncology|2025Cited by 8
Downregulation of XIAP expression induces apoptosis and sensitizes a panel of pediatric tumor cells to cytotoxic agentsSarah V. Holt, Guy Makin, Karen E. Brookes et al.|Molecular Cancer Therapeutics|2007Cited by 1